Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Sarah Finch (NPI 1144978271)

Field	Value
Entity Type	Individual
Organization	Sarah Finch
Address	3200 Plaza East Dr
City	Hutchinson
State	KS
ZIP	67502
Taxonomy	Family Nurse Practitioner
NPI Enumerated	March 17, 2022

Payer Source	Total Paid
Medicare	$6.2M
Medicaid	$0

Key Findings

This provider’s Medicare footprint is concentrated and operationally focused: total Medicare revenue is $6.2M while Medicaid billing is listed as none, so the practice is effectively single‑payer (Medicare) in scale and exposure. The NPI was enumerated on 2022-03-17 (~4 years ago), indicating a relatively recent public billing tenure but rapid accrual of significant Medicare revenue in a short window.

Revenue concentration is high — the top three Medicare codes by revenue (J0897 at 23.5%, J9271 at 20.6%, and J9299 at 9.4%) together account for 53.5% of Medicare revenue. Those three codes are all high-cost injectable oncology/biologic agents, implying the business is driven by drug administration rather than traditional office visits or non‑drug services.

The code mix and high ranks point to an infusion- or biologic-injection–centric operation: large shares come from J0897 (denosumab), J9271 (pembrolizumab), and J9299 (nivolumab), and multiple infusion/chemotherapy administration codes are prominent (96413, 96365, 96415, 96372). This pattern suggests the provider functions primarily as an outpatient infusion site administering oncology and specialty biologic therapies rather than a conventional primary‑care practice.

Several individual codes are national outliers, signaling dominant volumes for specific drugs or services: J0897 is an extreme outlier (rank #5 of 10057, 100th percentile) and J1439 is also an extreme outlier (rank #1 of 1209, 100th percentile), while infusion/chemo administration codes such as 96413 (rank #50 of 7514, 99th percentile) and 96365 (rank #37 of 8873, 100th percentile) are likewise extreme outliers. These rankings indicate market-leading throughput for certain injectable therapies and infusion sessions relative to national peers.

A broader set of biologic infusion codes are notably above typical national volumes: J9271 ranks #126 of 1841 (93th percentile; notably above typical), J3380 ranks #23 of 620 (96th percentile; notably above typical), and J3111 ranks #48 of 970 (95th percentile; notably above typical). Together with the extreme outliers, this mixture demonstrates consistent high-volume administration of specialty biologics rather than sporadic use.

Clinical visit E/M codes are a minor component of revenue: 99214 accounts for $28.4K (0.5% of Medicare revenue) and 99213 accounts for $25K (0.4% of Medicare revenue), both described as typical, unremarkable volumes relative to peers. This suggests the provider’s revenue is predominantly tied to drug and infusion services, and face-to-face evaluation and management encounters play a secondary financial role.

The absence of any Medicaid billing on file limits payer diversification and may concentrate payer risk and contracting leverage toward Medicare relationships; the provider’s business model appears optimized for Medicare-paid infusion services. That single-payer concentration could shape negotiation dynamics with payers and affect financial sensitivity to Medicare policy or reimbursement changes.

Operationally significant ancillary procedures also appear at high relative volumes — for example, 36591 (collection from implantable venous access device) ranks #6 of 699 (99th percentile; notably above typical) and add‑on infusion codes like 96415 rank #52 of 4959 (99th percentile; extreme outlier). These patterns reinforce that the practice delivers frequent, repeated infusion sessions and vascular access management as core services rather than episodic drug administration.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

51 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0897	Injection, denosumab, 1 mg	80,640	$20	$1.5M
J9271	Injection, pembrolizumab, 1 mg	29,600	$40	$1.3M
J9299	Injection, nivolumab, 1 mg	24,300	$20	$583.2K
J3380	Injection, vedolizumab, intravenous, 1 mg	33,000	$20	$561K
J1439	Injection, ferric carboxymaltose, 1 mg	519,000	$1	$519K
J3111	Injection, romosozumab-aqqg, 1 mg	60,270	$10	$482.2K
J1602	Injection, golimumab, 1 mg, for intravenous use	42,200	$10	$464.2K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	6,400	$30	$217.6K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	7,430	$30	$193.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,110	$80	$85.8K

Showing 1–10 of 51

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 51 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kansas Distribution

Sarah Finch — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kansas

Full comparison — all codes billed, vs. state median

51 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	9	20	28,900	$40	$1.1M
J9299	8	10	24,550	$20	$637.2K
J0129	12	20	8,000	$30	$291.5K
J3380	1	10	10,500	$20	$213.9K
J3111	1	10	17,700	$10	$198.5K
J1602	1	20	14,360	$10	$167.7K
J1745	1	20	3,110	$30	$96.9K
J0897	1	180	2,160	$20	$81.5K
J1439	1	10	41,250	$1	$66.1K
J0881	1	10	10,830	$1	$33.8K

Showing 1–10 of 51

Related Providers

Other providers that share a Tax Identification Number (TIN) with Sarah Finch, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Hutchinson Clinic, P.A. Inc.	KS	Rural Health Clinic/Center	$0	$9.1M
Hutchinson Clinic, P.A., Inc.	KS	Internal Medicine Physician	$0	$5.1M
Nicole Kirk	KS	Family Nurse Practitioner	$3M	$0
Michael Schekall	MN	Diagnostic Radiology Physician	$1.7M	$710
Costy Mattar	KS	Cardiovascular Disease Physician	$1.6M	$0
Hutchinson Clinic, P.A., Inc.	KS	Clinical Medical Laboratory	$1M	$288.6K
Fadi Estephan	KS	Hematology & Oncology Physician	$1.2M	$1.2K
Glenda Holzman	KS	Diagnostic Radiology Physician	$1.1M	$440
Hutchinson Clinic, PA, Inc.	KS	Rural Health Clinic/Center	$0	$1.1M
Humayun Ashraf	KS	Pulmonary Disease Physician	$849.4K	$0

Nearby Providers

Other providers in the same ZIP code as Sarah Finch, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Prairiestar Health Center, Inc	KS	Federally Qualified Health Center (FQHC)	$0	$13.9M
Hutchinson Regional Medical Center, Inc.	KS	General Acute Care Hospital	$0	$2.4M
Hutchinson Homestead Assisted Living, LLC	KS	Assisted Living Facility	$0	$2.4M
Hutchinson Ambulatory Surgery Center, LLC	KS	Ambulatory Surgical Clinic/Center	$1.3M	$846.5K
Hospice Of Reno County, Inc.	KS	Community Based Hospice Care Agency	$0	$1.8M
Kricket Young	KS	Pediatric Dentistry	$0	$1.6M
Vep Hutchinson Emergency Medical Group, LLC	KS	Emergency Medicine Physician	$0	$1.6M
Hutchinson Regional Medical Center, Inc.	KS	Land Ambulance	$0	$1.2M
Bladon Dialysis LLC	KS	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$805.5K
Russell Kelley	KS	Dermatology Physician	$508.8K	$0

Sarah Finch — Billing Profile & Reimbursement Data

Sign up for Sarah Finch — Billing Profile & Reimbursement Data policy alerts

Sarah Finch — Billing Profile & Reimbursement Data

Sign up for Sarah Finch — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References